

SHIONOGI & CORP LTD.

ISIN: JP3347200002 WKN: 4507 Asset Class: Stock



Company Profile

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic reagents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial figures, Fiscal year: from 01.04. to 31.03.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	784,192,000,000		659,205,000,000		556,238,000,000	
Common stock capital		21,279,000,000		21,279,000,000		21,279,000,000
Fixed assets	527,608,000,000		491,396,000,000		442,754,000,000	
Equity capital of a company		1,121,878,000,000		993,285,000,000		864,550,000,000
Cash and cash equivalents	309,224,000,000		254,420,000,000		276,173,000,000	
Accrued liabilities		12,867,000,000		15,412,000,000		16,318,000,000
Other assets	-		-		-	
Current liabilities		158,552,000,000		124,396,000,000		100,180,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		30,106,000,000		32,656,000,000		33,976,000,000
Different income		-		-		-
Other liabilities		4,926,000,000		5,708,000,000		5,301,000,000
Total assets	1,311,800,000,000	1,311,800,000,000	1,150,601,000,000	1,150,601,000,000	998,992,000,000	998,992,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	5,680	5,693	5,485
Equity ratio	87.19%	87.86%	88.39%
Debt-equity ratio	14.70%	13.82%	13.14%

Others

	2023	2022	2021
Tax Expense Rate	16.26%	10.16%	21.64%

SHIONOGI & CORP LTD.

ISIN: JP3347200002 WKN: 4507 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	426,684,000,000	335,138,000,000	297,177,000,000
Net income	184,965,000,000	114,185,000,000	111,858,000,000
EBIT	1,315,959,100	770,735,000	871,092,200
Operating income before taxes	220,365,000,000	126,288,000,000	143,018,000,000
Cash Flow	177,867,000,000	102,068,000,000	109,039,000,000
Net interest income	4,634,000,000	-62,000,000	216,000,000
Research and development expenses	102,392,000,000	72,996,000,000	54,249,000,000
Income taxes	35,836,000,000	12,829,000,000	30,956,000,000
Result from investments in subsidiaries, associates and other	-33,000,000	-20,000,000	0
Revenues per employee	458,235	359,097	330,498

Board of Directors

Fumi Takatsuki	Member of Supervisory Board
Hiroshi Ozaki	Member of Supervisory Board
Keiichi Ando	Member of Supervisory Board
Takuko Sawada	Member of Supervisory Board

Members of Management Board

Ph.D. Isao Teshirogi	Chairman of Managing Board
John Keller	Member of Executive Committee
Kazuhiro Hatanaka	Member of Executive Committee
Kohji Hanasaki	Member of Executive Committee
Noriyuki Kishida	Member of Executive Committee
Ryuichi Kiyama	Member of Executive Committee
Toshinobu Iwasaki	Member of Executive Committee
Yasuyoshi Isou	Member of Executive Committee